2023
DOI: 10.1016/j.jcis.2022.11.059
|View full text |Cite
|
Sign up to set email alerts
|

Insights into the mechanisms of interaction between inhalable lipid-polymer hybrid nanoparticles and pulmonary surfactant

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(9 citation statements)
references
References 57 publications
0
9
0
Order By: Relevance
“…Reducing the viscoelasticity of airway mucus is an area of constant research [64]. Also, nanoparticle-based delivery systems are becoming promising for treatment of respiratory treatment [65]. Advancement in nanotechnology using hybrid nanoparticles in the range of 200 nanometers have provided significant impetus to inhalation drug delivery, particularly in the management of pulmonary aspergillosis infection [66].…”
Section: Discussionmentioning
confidence: 99%
“…Reducing the viscoelasticity of airway mucus is an area of constant research [64]. Also, nanoparticle-based delivery systems are becoming promising for treatment of respiratory treatment [65]. Advancement in nanotechnology using hybrid nanoparticles in the range of 200 nanometers have provided significant impetus to inhalation drug delivery, particularly in the management of pulmonary aspergillosis infection [66].…”
Section: Discussionmentioning
confidence: 99%
“…33 DPPC was chosen due to its lung biocompatibility/tolerability, being the main endogenous component of the pulmonary surfactant, as well as for its ability to interact with it. 32,33,48 Additionally, DSPE-PEG 2000 -mannose was selected either for its ability to further stabilize the colloidal particles, and above all to favor the macrophage targeting thanks to mannose exposure on the outer shell of the Man-LPHNPs. 6,8,49 In fact, macrophages are increased in the lungs of COPD patients, and overexpress mannose receptors such as CD-206, CD-163 and CD-204 on their surface.…”
Section: Lipid-polymer Hybrid Nanoparticles (Lphnps) Productionmentioning
confidence: 99%
“…The latter lipid component was chosen with the aim to obtain mannosylated carriers (Man-LPHNPs) to actively target alveolar macrophages, while the DPPC was chosen due to the already documented interaction of inhalable hybrid DPPC-based nanoparticles with the pulmonary surfactant. 1,32…”
Section: Introductionmentioning
confidence: 99%
“…These interactions have the potential to disrupt the normal physiological function of lung surfactants or modify the behavior and outcomes of NPs. 14 Zhao et al 12 evaluated the interactions of PS with silica nanoparticles and polycyclic aromatic hydrocarbons (PAHs) and found that silica substantially changed the physical behavior and foaming capacity of PS. A possible reason for this is the competitive adsorption of PAHs with the PS components on silica.…”
Section: Anatomy and Biological Barriers Of The Lungmentioning
confidence: 99%
“…Because of the robust solubilization and adsorption suppression of PAHs by PS, when the NP + PAH complex enters the respiratory tract, the PAHs can be easily separated from silica, which may result in severe lung health consequences, as well as the toxicity of the NPs themselves. Xu et al 14 showed that the strength of the interaction of liposomal polymer nanoparticles (LPNs) with the PS component is strongly related to the mobility and surface charge of LPNs. LPNs with higher mobility have stronger interactions with PS, which allows them to accumulate within the PS, leading to a prolonged LPN retention time.…”
Section: Anatomy and Biological Barriers Of The Lungmentioning
confidence: 99%